Qtron Investments’s Regeneron Pharmaceuticals REGN Stock Holding History

Qtron Investments’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1,945	Closed	-$1.23M	–	417
2025 Q1	$1.23M	Buy	1,945 +530	+37%	+$365K	0.18%	141
2024 Q4	$1.01M	Hold	1,415	–	–	0.14%	175
2024 Q3	$1.49M	Sell	1,415 -436	-24%	-$485K	0.2%	113
2024 Q2	$1.95M	Hold	1,851	–	–	0.28%	63
2024 Q1	$1.78M	Buy	1,851 +240	+15%	+$228K	0.25%	80
2023 Q4	$1.41M	Hold	1,611	–	–	0.23%	84
2023 Q3	$1.33M	Buy	1,611 +368	+30%	+$289K	0.25%	83
2023 Q2	$893K	Hold	1,243	–	–	0.17%	159
2023 Q1	$1.02M	Sell	1,243 -298	-19%	-$225K	0.21%	122
2022 Q4	$1.11M	Buy	1,541 +97	+7%	+$71.6K	0.23%	102
2022 Q3	$995K	Buy	1,444 +877	+155%	+$552K	0.25%	100
2022 Q2	$335K	Buy	567 +203	+56%	+$132K	0.07%	307
2022 Q1	$254K	Buy	+364	New	+$230K	0.06%	312
2020 Q3	–	Sell	-587	Closed	-$366K	–	294
2020 Q2	$366K	Hold	587	–	–	0.15%	174
2020 Q1	$287K	Buy	+587	New	+$242K	0.17%	170

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Qtron Investments's REGN Position: Q2 2025 in Review

Qtron Investments sold out of Regeneron Pharmaceuticals (REGN) in Q2 2025, closing a stake of 1,945 shares — an estimated $1.23M sold.

Qtron Investments first reported a position in REGN in Q1 2020 and held it in 15 quarters. The position peaked at $1.95M in Q2 2024. 1,202 funds tracked by Wall St. Rank hold REGN as of Q2 2025.

Qtron Investments reported no remaining Regeneron Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Qtron Investments sold 1,945 Regeneron Pharmaceuticals shares in Q2 2025, an estimated $1.23M.
Qtron Investments first reported a position in Regeneron Pharmaceuticals in Q1 2020 and held it in 15 quarters.
Qtron Investments's Regeneron Pharmaceuticals position peaked at $1.95M in Q2 2024.
1,202 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2025.

Based on Qtron Investments's 13F filing for Q2 2025, filed 13 Aug 2025.